Technical Analysis for 1AD - Adalta Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Fell Below 200 DMA | Bearish | 4.35% | |
| 180 Bearish Setup | Bearish Swing Setup | 4.35% | |
| Wide Bands | Range Expansion | 4.35% | |
| Gapped Up | Strength | 4.35% |
| Alert | Time |
|---|---|
| Gap Down Closed | about 3 hours ago |
| Reversed from Down | about 3 hours ago |
| 200 DMA Support | about 3 hours ago |
| Gapped Down (Full) | about 7 hours ago |
| Down 3% | about 7 hours ago |
Get this analysis on your stocks daily!
Adalta Ltd Description
AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Health Medicine Disease Diseases Protein Heart Drug Discovery Animals In Vitro Eye Diseases Fibrosis Fibrotic Diseases Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.048 |
| 52 Week Low | 0.017 |
| Average Volume | 3,447,217 |
| 200-Day Moving Average | 0.024 |
| 50-Day Moving Average | 0.027 |
| 20-Day Moving Average | 0.026 |
| 10-Day Moving Average | 0.024 |
| Average True Range | 0.002 |
| RSI (14) | 50.00 |
| ADX | 25.23 |
| +DI | 37.453 |
| -DI | 24.719 |
| Chandelier Exit (Long, 3 ATRs) | 0.025 |
| Chandelier Exit (Short, 3 ATRs) | 0.028 |
| Upper Bollinger Bands | 0.031 |
| Lower Bollinger Band | 0.021 |
| Percent B (%b) | 0.27 |
| BandWidth | 36.641 |
| MACD Line | -0.001 |
| MACD Signal Line | -0.001 |
| MACD Histogram | -0.0005 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.026 | ||||
| Resistance 3 (R3) | 0.025 | 0.025 | 0.025 | ||
| Resistance 2 (R2) | 0.025 | 0.024 | 0.025 | 0.025 | |
| Resistance 1 (R1) | 0.024 | 0.024 | 0.025 | 0.025 | 0.025 |
| Pivot Point | 0.024 | 0.024 | 0.024 | 0.024 | 0.024 |
| Support 1 (S1) | 0.023 | 0.023 | 0.024 | 0.024 | 0.023 |
| Support 2 (S2) | 0.023 | 0.023 | 0.023 | 0.023 | |
| Support 3 (S3) | 0.022 | 0.023 | 0.023 | ||
| Support 4 (S4) | 0.023 |
